89bio director reports option cancellations under Roche merger terms
Rhea-AI Filing Summary
89bio, Inc. (ETNB) director Edward Morrow Atkinson III reported derivative transactions tied to the company’s change of control. On October 30, 2025, following Roche Holdings, Inc.’s tender offer and subsequent merger, multiple stock option grants were disposed of or cancelled pursuant to the merger terms.
Holders of options with an exercise price below the $14.50 per share cash consideration became entitled to cash equal to the in‑the‑money amount plus one non‑tradeable contingent value right (CVR) per underlying share. Each CVR provides potential contingent payments of up to an aggregate $6.00 per share, payable upon specified milestones under the CVR Agreement. Options with exercise prices equal to or above $14.50 but less than $20.50 were eligible to receive CVRs (and potential milestone payments as defined), while options at or above $20.50 were cancelled without payment.
Reported grants included options with exercise prices of $4.44, $14.70, $9.98, and $9.60, each showing 0 derivative securities beneficially owned following the transactions, held directly.
Positive
- None.
Negative
- None.
Insights
Director’s options settled under Roche–89bio merger terms; Form 4 is administrative.
The filing reflects option treatment triggered by the closing of Roche’s tender offer and the subsequent merger. The core mechanics: cash of $14.50 per share plus one CVR per share, with CVRs allowing up to an additional $6.00 per share upon milestone achievements under the CVR Agreement.
Option outcomes are formulaic. In-the-money options receive cash equal to the excess over $14.50 per share plus CVRs. Options with strikes at or above $14.50 but below $20.50 receive CVRs and contingent cash per the stated formula. Options at or above $20.50 are cancelled without consideration.
This is a post‑closing settlement disclosure rather than a new financing event. It lists methods and amounts defined by the merger agreement; actual CVR value depends on milestone attainment, which this excerpt does not specify.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 20,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 27,400 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 45,150 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 56,400 | $0.00 | -- |
Footnotes (1)
- Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.
